EA201270360A1 - Терапевтическое средство от тревожных расстройств - Google Patents

Терапевтическое средство от тревожных расстройств

Info

Publication number
EA201270360A1
EA201270360A1 EA201270360A EA201270360A EA201270360A1 EA 201270360 A1 EA201270360 A1 EA 201270360A1 EA 201270360 A EA201270360 A EA 201270360A EA 201270360 A EA201270360 A EA 201270360A EA 201270360 A1 EA201270360 A1 EA 201270360A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disorders
alarm
therapeutic means
therapeutic
pharmaceutically acceptable
Prior art date
Application number
EA201270360A
Other languages
English (en)
Other versions
EA023728B1 (ru
Inventor
Юня Касе
Томоюки Канда
Original Assignee
Киова Хакко Кирин Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201270360(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Киова Хакко Кирин Ко., Лтд. filed Critical Киова Хакко Кирин Ко., Лтд.
Publication of EA201270360A1 publication Critical patent/EA201270360A1/ru
Publication of EA023728B1 publication Critical patent/EA023728B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Описывается терапевтическое и/или профилактическое средство от тревожного расстройства, которое содержит в качестве активного ингредиента производное тиазола, представленное общей формулой (I) (где Rпредставляет собой арильную группу или подобные и Rпредставляет пиридильную группу или подобные), или его фармацевтически приемлемую соль.
EA201270360A 2009-09-02 2010-09-02 Терапевтическое средство от тревожных расстройств EA023728B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009202894 2009-09-02
PCT/JP2010/064989 WO2011027806A1 (ja) 2009-09-02 2010-09-02 不安障害治療剤

Publications (2)

Publication Number Publication Date
EA201270360A1 true EA201270360A1 (ru) 2012-09-28
EA023728B1 EA023728B1 (ru) 2016-07-29

Family

ID=43649340

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270360A EA023728B1 (ru) 2009-09-02 2010-09-02 Терапевтическое средство от тревожных расстройств

Country Status (31)

Country Link
US (1) US20120172362A1 (ru)
EP (1) EP2474544B1 (ru)
JP (1) JP5663485B2 (ru)
KR (2) KR20120047311A (ru)
CN (1) CN102482271A (ru)
AU (1) AU2010290424C1 (ru)
BR (1) BR112012004850A2 (ru)
CA (1) CA2772922C (ru)
CL (1) CL2012000533A1 (ru)
CY (1) CY1119483T1 (ru)
DK (1) DK2474544T3 (ru)
DO (1) DOP2012000056A (ru)
EA (1) EA023728B1 (ru)
ES (1) ES2643840T3 (ru)
GE (1) GEP20156225B (ru)
HR (1) HRP20171418T1 (ru)
HU (1) HUE036543T2 (ru)
IL (1) IL218320A (ru)
LT (1) LT2474544T (ru)
MA (1) MA33619B1 (ru)
ME (1) ME02877B (ru)
MX (1) MX2012002529A (ru)
NZ (1) NZ598754A (ru)
PL (1) PL2474544T3 (ru)
PT (1) PT2474544T (ru)
RS (1) RS56401B1 (ru)
SI (1) SI2474544T1 (ru)
TN (1) TN2012000093A1 (ru)
UA (1) UA113383C2 (ru)
WO (1) WO2011027806A1 (ru)
ZA (1) ZA201202347B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1700856E (pt) * 2003-12-26 2016-02-19 Kyowa Hakko Kirin Co Ltd Derivado de tiazole
MA41090A (fr) * 2014-12-03 2017-10-10 H Lundbeck As Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
JOP20200093A1 (ar) 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
JO3544B1 (ar) * 2015-03-19 2020-07-05 Kyowa Kirin Co Ltd عامل علاجي للاختلال الوظيفي في الفص الجبهي
IL280639B (en) 2018-09-17 2022-07-01 Yungjin Pharmaceutical Co Ltd History of thiazoles and their pharmaceutically acceptable salts

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116967C (en) 1992-07-08 2003-08-19 Fumio Suzuki Antidepressants
ES2264210T3 (es) 1997-09-05 2006-12-16 Kyowa Hakko Kogyo Co., Ltd. Derivados de xantina para el tratamiento de la isquemia cerebral.
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
EP1177797A1 (en) * 1999-05-12 2002-02-06 Fujisawa Pharmaceutical Co., Ltd. Novel use
US20030139395A1 (en) * 2001-09-13 2003-07-24 Schering Corporation Combination of an adenosine A2a receptor antagonist and an antidepressant or anxiolytic
US6620811B2 (en) 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
CN1787821A (zh) * 2003-06-10 2006-06-14 协和发酵工业株式会社 一种治疗焦虑症的方法
PT1700856E (pt) * 2003-12-26 2016-02-19 Kyowa Hakko Kirin Co Ltd Derivado de tiazole
WO2006137527A1 (ja) * 2005-06-23 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. チアゾール誘導体
WO2007015528A1 (ja) * 2005-08-02 2007-02-08 Kyowa Hakko Kogyo Co., Ltd. 睡眠障害の治療および／または予防剤
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою

Also Published As

Publication number Publication date
JPWO2011027806A1 (ja) 2013-02-04
EP2474544A1 (en) 2012-07-11
CA2772922A1 (en) 2011-10-03
PT2474544T (pt) 2017-10-03
AU2010290424C1 (en) 2016-02-18
EP2474544B1 (en) 2017-07-12
CA2772922C (en) 2017-11-21
US20120172362A1 (en) 2012-07-05
AU2010290424A1 (en) 2012-04-19
EA023728B1 (ru) 2016-07-29
HRP20171418T1 (hr) 2017-11-03
IL218320A0 (en) 2012-04-30
CL2012000533A1 (es) 2012-09-14
DK2474544T3 (en) 2017-10-02
TN2012000093A1 (en) 2013-09-19
WO2011027806A1 (ja) 2011-03-10
ME02877B (me) 2018-04-20
CY1119483T1 (el) 2018-03-07
ZA201202347B (en) 2015-11-25
MA33619B1 (fr) 2012-09-01
CN102482271A (zh) 2012-05-30
GEP20156225B (en) 2015-01-26
HUE036543T2 (hu) 2018-07-30
IL218320A (en) 2016-06-30
KR20120047311A (ko) 2012-05-11
DOP2012000056A (es) 2012-06-30
MX2012002529A (es) 2012-04-11
KR20170044768A (ko) 2017-04-25
JP5663485B2 (ja) 2015-02-04
RS56401B1 (sr) 2018-01-31
ES2643840T3 (es) 2017-11-24
BR112012004850A2 (pt) 2020-06-23
SI2474544T1 (sl) 2017-11-30
AU2010290424B2 (en) 2015-11-05
UA113383C2 (xx) 2017-01-25
EP2474544A4 (en) 2013-01-23
LT2474544T (lt) 2017-10-25
NZ598754A (en) 2014-08-29
PL2474544T3 (pl) 2017-12-29

Similar Documents

Publication Publication Date Title
EA201270359A1 (ru) Терапевтическое средство от расстройств настроения
MY192603A (en) 1,3-benzodioxole derivative
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
MX2020011652A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
RS54123B1 (en) THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE
RS54730B1 (sr) Inhibitori beta sekretaze
CA2914620C (en) Heterocyclic derivatives and use thereof
UA107753C2 (xx) ЗАМІЩЕНІ ІНГІБІТОРИ АЦЕТИЛ-СоА КАРБОКСИЛАЗИ
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
RS53613B1 (en) COMPOUNDS, COMPOSITIONS, AND PROCEDURES FOR TREATMENT OF BETA-AMYLOID DISEASES AND SYNUCLEINOPATHY
CY1119483T1 (el) Θεραπευτικος παραγων για τις αγχωδεις διαταραχες
NZ596362A (en) Therapeutic agent for motor disorders
MX2016002718A (es) Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).
PH12016502246A1 (en) Carboxamide derivatives
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
TN2016000491A1 (en) Carboxamide derivatives.
WO2011159124A3 (ko) Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
MY167075A (en) Benzodioxole derivative and preparation method and use thereof
PH12015501056A1 (en) 2-pyridone compound
MX2012012410A (es) Agente terapeutico y agente preventivo para enfermedad de alzheimer.
WO2012125663A3 (en) Cyclohexane substituted amino cyclopentane derivatives as useful ccr2 antagonists
EA201300160A1 (ru) 2,3,5-тризамещенные тиофены и их применение
EP2463293A4 (en) AZACYCLOHEXAPEPTIDE BZW. ITS PHARMACEUTICAL ACCEPTABLE SALT, MANUFACTURING PROCESS AND USE

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG MD TJ TM

TC4A Change in name of a patent proprietor in a eurasian patent